Table 2

The prevalence of antibody to HCMVpp65 sub-fragments in patients with autoimmunity and healthy controls

Antigens

SLE

SSc

SS

RA

Normal


Age (years)

11 to 77

48 to 79

14 to 79

21 to 81

31 to 73

Mean (years)

33.8

61.9

53.4

54.6

63.2

Total specimen

61

20

13

50

45

Female (%)

93.4

95

92.3

80

57.8

Responsiveness

pp651 to 167 (%)

4/61 (7)

3/20 (15)

5/13 (38)

0/50 (0)

6/45 (13)

pp65167 to 336 (%)

12/61 (20)

5/20 (25)

3/13 (23)

16/50 (32)

9/45 (20)

pp65336 to 561 (%)

37/61 (61)

4/20 (20)

2/13 (15)

7/50 (14)

2/45 (4)

pp65336 to 379 (%)

0/30 (0)

pp65379 to 455 (%)

22/30 (73)

pp65455 to 561 (%)

3/30 (10)

pp65336 to 448 (%)

17/22 (77)

pp65336 to 439 (%)

16/22 (73)

pp65336 to 422 (%)

9/22 (41)


RA, rheumatoid arthritis; SS, Sjögren's syndrome; SSc, systemic sclerosis. For immunoblot and ELISA assay, detection of anti-pp65 sub-fragments antibody was tested with purified human cytomegalovirus (HCMV) virions, as described in materials and methods. The HCMV positivity is defined by mean + 3 s.e.m of normal control. The results are representative of triplicated experiments.

Hsieh et al. Arthritis Research & Therapy 2011 13:R162   doi:10.1186/ar3481

Open Data